Do analysts prefer CMND or ATON?

Portage Biotech has a consensus target price of $2.00, indicating a potential upside of 502.41%. Given Portage Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Portage Biotech is more favorable than Clearmind Medicine. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clearmind Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Portage Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, CMND or ATON?

Portage Biotech is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clearmind Medicine N/A N/A -$3.86M -$139.98 N/A Portage Biotech N/A N/A -$6.77M -$8.18 N/A

Is CMND or ATON more profitable?

Portage Biotech's return on equity of 0.00% beat Clearmind Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Clearmind Medicine N/A -143.79% -88.51% Portage Biotech N/A N/A N/A

Does the media refer more to CMND or ATON?

In the previous week, Clearmind Medicine had 3 more articles in the media than Portage Biotech. MarketBeat recorded 4 mentions for Clearmind Medicine and 1 mentions for Portage Biotech. Clearmind Medicine's average media sentiment score of 0.69 beat Portage Biotech's score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clearmind Medicine 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Portage Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is EGRX or CMND more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat Clearmind Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A Clearmind Medicine N/A -143.79% -88.51%

Does the media prefer EGRX or CMND?

In the previous week, Clearmind Medicine had 3 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 4 mentions for Clearmind Medicine and 1 mentions for Eagle Pharmaceuticals. Clearmind Medicine's average media sentiment score of 0.69 beat Eagle Pharmaceuticals' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eagle Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Clearmind Medicine 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, RVPH or CMND?

Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Reviva Pharmaceuticals N/A N/A -$19.86M -$4.06 N/A Clearmind Medicine N/A N/A -$3.86M -$139.98 N/A

Is RVPH or CMND more profitable?

Clearmind Medicine's return on equity of -143.79% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Reviva Pharmaceuticals N/A -391.58% -119.08% Clearmind Medicine N/A -143.79% -88.51%

Do analysts recommend CMND or ACXP?

Acurx Pharmaceuticals has a consensus price target of $31.00, suggesting a potential upside of 2,083.10%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Clearmind Medicine. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clearmind Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, CMND or ACXP?

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clearmind Medicine N/A N/A -$3.86M -$139.98 N/A Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A

Is CMND or ACXP more profitable?

Clearmind Medicine's return on equity of -143.79% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Clearmind Medicine N/A -143.79% -88.51% Acurx Pharmaceuticals N/A -153.92% -101.69%

Do analysts recommend CMND or ASBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clearmind Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CMND or ASBP more profitable?

Aspire Biopharma's return on equity of 0.00% beat Clearmind Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Clearmind Medicine N/A -143.79% -88.51% Aspire Biopharma N/A N/A -398.04%

Does the media refer more to CMND or ASBP?

In the previous week, Clearmind Medicine had 1 more articles in the media than Aspire Biopharma. MarketBeat recorded 4 mentions for Clearmind Medicine and 3 mentions for Aspire Biopharma. Clearmind Medicine's average media sentiment score of 0.69 beat Aspire Biopharma's score of 0.45 indicating that Clearmind Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clearmind Medicine 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aspire Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Clearmind Medicine (CMND) Competitors

$1.61 -0.05 (-3.01%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.64 +0.03 (+1.86%)

As of 07/24/2026 07:34 PM Eastern

Compare

CMND vs. ATON, EGRX, RVPH, ACXP, and ASBP

Should you buy Clearmind Medicine stock or one of its competitors? MarketBeat compares Clearmind Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Clearmind Medicine include Portage Biotech (ATON), Eagle Pharmaceuticals (EGRX), Reviva Pharmaceuticals (RVPH), Acurx Pharmaceuticals (ACXP), and Aspire Biopharma (ASBP). These companies are all part of the "pharmaceutical products" industry.

How does Clearmind Medicine compare to Portage Biotech?

Clearmind Medicine (NASDAQ:CMND) and Portage Biotech (NASDAQ:ATON) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Portage Biotech is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clearmind Medicine	N/A	N/A	-$3.86M	-$139.98	N/A
Portage Biotech	N/A	N/A	-$6.77M	-$8.18	N/A

96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 13.4% of Portage Biotech shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Portage Biotech's return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clearmind Medicine	N/A	-143.79%	-88.51%
Portage Biotech	N/A	N/A	N/A

In the previous week, Clearmind Medicine had 3 more articles in the media than Portage Biotech. MarketBeat recorded 4 mentions for Clearmind Medicine and 1 mentions for Portage Biotech. Clearmind Medicine's average media sentiment score of 0.69 beat Portage Biotech's score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clearmind Medicine	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Portage Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Portage Biotech has a consensus target price of $2.00, indicating a potential upside of 502.41%. Given Portage Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Portage Biotech is more favorable than Clearmind Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clearmind Medicine	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Portage Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Clearmind Medicine has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Portage Biotech has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

Summary

Clearmind Medicine and Portage Biotech tied by winning 6 of the 12 factors compared between the two stocks.

How does Clearmind Medicine compare to Eagle Pharmaceuticals?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

In the previous week, Clearmind Medicine had 3 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 4 mentions for Clearmind Medicine and 1 mentions for Eagle Pharmaceuticals. Clearmind Medicine's average media sentiment score of 0.69 beat Eagle Pharmaceuticals' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eagle Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Clearmind Medicine	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eagle Pharmaceuticals' return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
Clearmind Medicine	N/A	-143.79%	-88.51%

85.4% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Eagle Pharmaceuticals has higher revenue and earnings than Clearmind Medicine. Clearmind Medicine is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.02	$35.64M	$1.18	0.31
Clearmind Medicine	N/A	N/A	-$3.86M	-$139.98	N/A

Eagle Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Summary

Eagle Pharmaceuticals beats Clearmind Medicine on 8 of the 11 factors compared between the two stocks.

How does Clearmind Medicine compare to Reviva Pharmaceuticals?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

In the previous week, Clearmind Medicine had 4 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 4 mentions for Clearmind Medicine and 0 mentions for Reviva Pharmaceuticals. Clearmind Medicine's average media sentiment score of 0.69 beat Reviva Pharmaceuticals' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company	Overall Sentiment
Reviva Pharmaceuticals	Neutral
Clearmind Medicine	Positive

Clearmind Medicine's return on equity of -143.79% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
Clearmind Medicine	N/A	-143.79%	-88.51%

Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A
Clearmind Medicine	N/A	N/A	-$3.86M	-$139.98	N/A

Reviva Pharmaceuticals presently has a consensus target price of $66.67, suggesting a potential upside of 14,006.36%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Reviva Pharmaceuticals is more favorable than Clearmind Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Clearmind Medicine	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Reviva Pharmaceuticals has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Summary

Clearmind Medicine beats Reviva Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Clearmind Medicine compare to Acurx Pharmaceuticals?

Clearmind Medicine (NASDAQ:CMND) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

In the previous week, Clearmind Medicine had 3 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 4 mentions for Clearmind Medicine and 1 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 1.89 beat Clearmind Medicine's score of 0.69 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Clearmind Medicine	Positive
Acurx Pharmaceuticals	Very Positive

Clearmind Medicine's return on equity of -143.79% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clearmind Medicine	N/A	-143.79%	-88.51%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clearmind Medicine	N/A	N/A	-$3.86M	-$139.98	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Acurx Pharmaceuticals has a consensus price target of $31.00, suggesting a potential upside of 2,083.10%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Clearmind Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clearmind Medicine	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Clearmind Medicine has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.05, meaning that its share price is 305% less volatile than the broader market.

Summary

Clearmind Medicine beats Acurx Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Clearmind Medicine compare to Aspire Biopharma?

Clearmind Medicine (NASDAQ:CMND) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

Clearmind Medicine has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.15, meaning that its share price is 85% less volatile than the broader market.

96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Clearmind Medicine had 1 more articles in the media than Aspire Biopharma. MarketBeat recorded 4 mentions for Clearmind Medicine and 3 mentions for Aspire Biopharma. Clearmind Medicine's average media sentiment score of 0.69 beat Aspire Biopharma's score of 0.45 indicating that Clearmind Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clearmind Medicine	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aspire Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clearmind Medicine	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aspire Biopharma's return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clearmind Medicine	N/A	-143.79%	-88.51%
Aspire Biopharma	N/A	N/A	-398.04%

Clearmind Medicine has higher earnings, but lower revenue than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clearmind Medicine	N/A	N/A	-$3.86M	-$139.98	N/A
Aspire Biopharma	$34.56K	272.08	-$24.48M	-$116.67	N/A

Summary

Clearmind Medicine beats Aspire Biopharma on 7 of the 12 factors compared between the two stocks.

Get Clearmind Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMND vs. The Competition

Export

Metric	Clearmind Medicine	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.64M	$3.07B	$6.87B	$12.26B
Dividend Yield	N/A	2.07%	2.67%	9.79%
P/E Ratio	-0.01	20.29	27.14	23.64
Price / Sales	N/A	485.19	517.06	88.99
Price / Cash	N/A	27.62	50.54	59.64
Price / Book	0.11	4.13	10.28	6.07
Net Income	-$3.86M	$65.94M	$3.60B	$331.99M
7 Day Performance	-17.01%	-4.16%	-1.27%	-0.63%
1 Month Performance	-35.34%	-3.76%	-0.37%	-2.00%
1 Year Performance	-99.61%	9.94%	18.30%	13.62%

Clearmind Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMND Clearmind Medicine	1.74 of 5 stars	$1.61 -3.0%	N/A	-99.6%	$1.64M	N/A	N/A	N/A	Short Interest Decrease
ATON Portage Biotech	1.0486 of 5 stars	$0.33 +3.8%	$2.00 +502.4%	N/A	$7.78M	N/A	N/A	6	News Coverage Gap Up High Trading Volume
EGRX Eagle Pharmaceuticals	N/A	$0.60 flat	N/A	-90.0%	$7.73M	$257.55M	0.50	100	Gap Down
RVPH Reviva Pharmaceuticals	1.8425 of 5 stars	$0.58 flat	$66.67 +11,309.7%	-94.5%	$7.66M	N/A	N/A	5	Gap Down
ACXP Acurx Pharmaceuticals	3.867 of 5 stars	$1.76 +0.7%	$31.00 +1,659.4%	-83.9%	$7.60M	N/A	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMND) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Clearmind Medicine (CMND) Competitors

CMND vs. ATON, EGRX, RVPH, ACXP, and ASBP

How does Clearmind Medicine compare to Portage Biotech?

Summary

How does Clearmind Medicine compare to Eagle Pharmaceuticals?

Summary

How does Clearmind Medicine compare to Reviva Pharmaceuticals?

Summary

How does Clearmind Medicine compare to Acurx Pharmaceuticals?

Summary

How does Clearmind Medicine compare to Aspire Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMND vs. The Competition

Clearmind Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Clearmind Medicine (CMND) Competitors

CMND vs. ATON, EGRX, RVPH, ACXP, and ASBP

How does Clearmind Medicine compare to Portage Biotech?

Which has higher valuation and earnings, CMND or ATON?

Do institutionals & insiders believe in CMND or ATON?

Is CMND or ATON more profitable?

Does the media refer more to CMND or ATON?

Do analysts prefer CMND or ATON?

Which has more risk and volatility, CMND or ATON?

Summary

How does Clearmind Medicine compare to Eagle Pharmaceuticals?

Does the media prefer EGRX or CMND?

Is EGRX or CMND more profitable?

Do institutionals and insiders hold more shares of EGRX or CMND?

Which has preferable valuation & earnings, EGRX or CMND?

Which has more risk & volatility, EGRX or CMND?

Summary

How does Clearmind Medicine compare to Reviva Pharmaceuticals?

Does the media prefer RVPH or CMND?

Is RVPH or CMND more profitable?

Which has stronger valuation and earnings, RVPH or CMND?

Do analysts rate RVPH or CMND?

Do insiders and institutionals hold more shares of RVPH or CMND?

Which has more risk & volatility, RVPH or CMND?

Summary

How does Clearmind Medicine compare to Acurx Pharmaceuticals?

Does the media refer more to CMND or ACXP?

Is CMND or ACXP more profitable?

Which has stronger earnings and valuation, CMND or ACXP?

Do insiders & institutionals have more ownership in CMND or ACXP?

Do analysts recommend CMND or ACXP?

Which has more volatility and risk, CMND or ACXP?

Summary

How does Clearmind Medicine compare to Aspire Biopharma?

Which has more volatility & risk, CMND or ASBP?

Do institutionals and insiders have more ownership in CMND or ASBP?

Does the media refer more to CMND or ASBP?

Do analysts recommend CMND or ASBP?

Is CMND or ASBP more profitable?

Which has better valuation and earnings, CMND or ASBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMND vs. The Competition

Clearmind Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools